Putnam Investments
ONCE

Putnam Investments’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Putnam Investments’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-31,093
Closed -$1.7M – 1169
2018
Q3 		$1.7M Buy
31,093
+18,232
+142% +$1.25M ﹤0.01% 783
2018
Q2 		$1.06M Buy
+12,861
New +$993K ﹤0.01% 843

Other funds holding ONCE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Putnam Investments's ONCE Position: Q4 2018 in Review

Putnam Investments sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2018, closing a stake of 31,093 shares — an estimated $1.7M sold.

Putnam Investments first reported a position in ONCE in Q2 2018 and held it in 2 quarters. The position peaked at $1.7M in Q3 2018. 157 funds tracked by Wall St. Rank hold ONCE as of Q4 2018.

  • Putnam Investments reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Putnam Investments sold 31,093 Spark Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $1.7M.
  • Putnam Investments first reported a position in Spark Therapeutics, Inc. Common Stock in Q2 2018 and held it in 2 quarters.
  • Putnam Investments's Spark Therapeutics, Inc. Common Stock position peaked at $1.7M in Q3 2018.
  • 157 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Putnam Investments's 13F filing for Q4 2018, filed 14 Feb 2019.